Skip to main content

Advertisement

Table 1 Characteristics of 29 selected systematic reviews

From: Wasted research when systematic reviews fail to provide a complete and up-to-date evidence synthesis: the example of lung cancer

Systematic review Last search Publication date Number of trials Funding source Intervention Comparator Specific treatment Different treatments lumped together Different types of treatments lumped together
Bonfill 2002 Jul 2001 Apr 2001 1 Non-industry CTx PBO or BSC No Yes No
Tassinari 2009 Jul 2008 Feb 2009 3 NR CTx or EGFRTKI BSC No Yes Yes
Yang 2014 Dec 2013 May 2014 2 NR EGFRTKI PBO No Yes No
Wong 2013 SMay 2012 Oct 2013 4 NR EGFRTKI CTx or PBO No Yes Yes
Barlesi 2006 Feb 2005 Dec 2005 4 NR DOC CTx or BSC No Yes Yes
Al-Saleh 2012 Jan 2010 Feb 2012 1 Industry PEM CTx Yes Yes No
Perez-Moreno 2014 Apr 2012 Mar 2014 1 Non-industry PEM CTx Yes Yes No
Jiang 2011 Feb 2010 Dec 2010 4 Non-industry GEF DOC Yes No No
Qi 2012c Mar 2012 Oct 2012 8 Non-industry EGFRTKI CTx No Yes No
Gao 2013 NR Jun 2013 3 NR EGFRTKI CTx No Yes No
Lee 2014 Dec 2013 Apr 2014 7 Non-industry EGFRTKI CTx No Yes No
Zhao 2014 Jul 2013 Apr 2014 6 Non-industry EGFRTKI CTx No Yes No
Li 2014b Jul 2013 Jul 2014 10 None EGFRTKI CTx No Yes No
Vale 2014 Jan 2014 Nov 2014 14 Non-industry EGFRTKI CTx No Yes No
Qi 2012a Mar 2011 May 2011 8 NR DOC + (CTx or TT) DOC No Yes Yes
Jin 2014* Dec 2013 Sep 2014 12 Non-industry DOC + (CTx or TT) DOC No Yes Yes
Qi 2012b May 2011 Jan 2012 5 NR PEM + (CTx or TT) PEM No Yes Yes
Sun 2014 Feb 2012 Apr 2014 4 NR PEM + (CTx or TT) PEM No Yes Yes
Qi 2011 Jul 2011 Oct 2011 4 NR CTx + VAN or VAN CTx or EGFRTKI Yes Yes Yes
Tao 2012 Sep 2011 Mar 2012 5 NR CTx + VAN or VAN CTx or EGFRTKI Yes Yes Yes
Tassinari 2012 Jun 2010 Dec 2012 4 NR DOC CTx or EGFRTKI No Yes Yes
Qi 2013 May 2012 Feb 2013 8 Non-industry ERL + TT ERL No Yes No
Cui 2013 Dec 2011 Apr 2013 8 Non-industry BEV + (CTx or EGFRTKI) CTx or EGFRTKI Yes Yes Yes
      EGFRTKI CTx or PBO No Yes Yes
Li 2014a Dec 2013 Apr 2014 14 None CTx + TT CTx No Yes No
Liang 2014 Jan 2014 Oct 2014 10 Non-industry MATKI + (CTx or EGFRTKI) or MATKI CTx or EGFRTKI or PBO No Yes Yes
Sun 2015 Oct 2014 Jan 2015 2 NR BEV + EGFRTKI EGFRTKI No Yes No
Xiao 2015 Sep 2014 Feb 2015 5 Non-industry CTx + EGFRTKI CTx or EGFRTKI No Yes Yes
Hawkins 2009 Oct 2007 Apr 2009 6 Industry DOC vs PEM vs ERL vs GEF No No No
Popat 2015 Mar 2014 Dec 2014 9 Industry CTx vs TT vs CTx + TT vs (PBO or BSC) No No No
  1. *Update of Qi 2012a; network meta-analysis; conference abstracts. BEV: bevacizumab; BSC: best supportive care; CTx: monochemotherapy; DOC: docetaxel; EGFRTKI: EGFR tyrosine kinase inhibitors; ERL: erlotinib; GEF: gefitinib; MATKI: multi-targeted antiangiogenic tyrosine kinase inhibitors; NR: not reported; PBO: placebo; PEM: pemetrexed; TT: targeted therapy; VAN: vandetanib